Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?

Reviews in Endocrine and Metabolic Disorders

Volumn 7, Issue 1-2, 2006, Pages 101-112

  Chaiamnuay, Sumapa ^a   Saag, Kenneth G ^a,b  

^a University of Alabama at Birmingham   (United States)

^b FOT 820 ^*  (United States)

Author keywords

Bisphosphonates; Postmenopausal osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; EB 1053; ESTROGEN; ETIDRONIC ACID; GERANYLTRANSFERASE; IBANDRONIC ACID; INCADRONIC ACID; MINODRONIC ACID; NERIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OLPADRONIC ACID; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADD ON THERAPY; APOPTOSIS; ARTHRALGIA; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE TURNOVER; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS STRICTURE; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HETEROTOPIC OSSIFICATION; HIP FRACTURE; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; LONG TERM CARE; MONOTHERAPY; MYALGIA; NONHUMAN; OSTEOCLAST; PAGET BONE DISEASE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; STOMACH ULCER; TREATMENT DURATION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; LONG-TERM CARE; MODELS, BIOLOGICAL; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 33846015046     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-006-9008-y     Document Type: Review

References (80)

1. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25(1):97-106.
2. Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003;37(4):225-38.
3. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(Suppl 12):2961-78.
4. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28(5):465-73.
5. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104(10):1363-74.
6. Boonen S, Haentjens P, Vandenput L, Vanderschueren D. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 2004;255(1):1-12.
7. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333(22):1437-43.
8. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 1998;280(24):2077-82.
9. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41.
10. Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9(8):1137-41.
11. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85(11):4118-24.
12. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9(5):461-8.
13. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23(4):508-16.
14. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16(5):468-74.
15. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12(1):1-12.
16. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21(9):1453-60.
17. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119(4 Suppl 1):S18-24.
18. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Jama 1999;282(14):1344-52.
19. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11(1):83-91.
20. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344(5):333-40.
21. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23(4):517-23.
22. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71 2: 103-11.
23. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20(1):141-51.
24. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8): 1241-9.
25. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006.
26. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21(12):1895-903.
27. Emkey MZR, Lewiecki EM, Burdeska A, Mairon N, Rowell L, Eisman JA. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. 2005.
28. Sambrook P, Olszynski WP, Leigh C, Masanauskaite D, Bonvoisin B, Emkey R. Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: the DIVA study. Arthritis Rheum 2005;52(Suppl 9):S296.
29. Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976;20(5):593-604.
30. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323(2):73-9.
31. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95(6):557-67.
32. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997;103(6):468-76.
33. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001;12(2):140-51.
34. Didronel: Label information. http://wwwfdagov/cder/foi/label/2006/ 017831s054lblpdf.
35. van Staa TP, Leufkens H, Abenhaim L, Cooper C. Postmarketing surveillance of the safety of cyclic etidronate. Pharmacotherapy 1998;18(5):1121-8.
36. Ryan PJ, Blake GM, Davie M, Haddaway M, Gibson T, Fogelman I. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. Osteoporos Int 2000;11(2):171-6.
37. Pamidronate: Label information. http://wwwfdagov/cder/foi/label/2005/ 020036s032lblpdf.
38. Peretz A, Body JJ, Dumon JC, et al. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996;25(1):69-75.
39. Thiebaud D, Burckhardt P, Melchior J, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994;4(2):76-83.
40. Cauza E, Etemad M, Winkler F, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 2004;29(5):431-6.
41. Chan SS, Nery LM, McElduff A, et al. Intravenous pamidronate in the treatment and prevention of osteoporosis. Intern Med J 2004;34(4):162-6.
42. Morabito N, Gaudio A, Lasco A, et al. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 2003;14(6):500-6.
43. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346(9):653-61.
44. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84(9):3076-81.
45. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000;85(2):720-6.
46. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86(5):1890-7.
47. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Jama 2003;289(19):2525-33.
48. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87(3):985-92.
49. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006;119(4 Suppl 1):S12-7.
50. Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002;47(8):1665-78.
51. Ribeiro A, DeVault KR, Wolfe III JT, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47(6):525-8.
52. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Path 1999;12(12):1152-7.
53. Lichtenberger LM, Romero JJ, Gibson GW, Blank MA. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 2000;45(9):1792-801.
54. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95(11):3112-7.
55. Graham DY, Malaty HM, Goodgame R. Primary aminobisphosphonates: a new class of gastrotoxic drugs - comparison of alendronate and aspirin. Am J Gastroenterol 1997;92(8):1322-5.
56. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999;13(4):515-9.
57. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350(12):1189-99.
58. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77(3):262-70.
59. Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119(3):631-8.
60. Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002;29(9):1965-74.
61. Epstein S, Delmas PD, Emkey R, Wilson KM, Hiltbrunner V, Schimmer RC. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas 2006;54(1):1-10.
62. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34.
63. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144(10):753-61.
64. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76(4):266-83.
65. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22):6538-44.
66. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8(5):1080-4.
67. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15(4):613-20.
68. Allen M, Iwata K, Phipps, R, Burr, DB. Risedronate and Alendronate similarly suppress remodelling and increase microdamage in beagles after 1 year of treatment at clinical doses. JBMR 2005.
69. Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 1984;304(1121):509-18.
70. Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 2001;86(4):1835-6.
71. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19(8):1259-69.
72. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75(6):462-8.
73. Recker R. Alendronate effects on histomorphometric parameters: is there evidence for over-suppression of turnover? JMBR 2005
74. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294-301.
75. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90(3):1897-9.
76. Emkey R, Zaidi M, Lewiecki EM, Burdeska A, Mairon N, Rowell L, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. 2005.
77. Fosamax: Label information. (http://www.fda.gov/cder/foi/label/2005/ 020560s038_021575s007lbl.pdf).
78. Actonel: Label information. (http://www.fda.gov/cder/foi/label/2006/ 020835s019,%20021823s002lbl.pdf).
79. Boniva: Label information. (http://wwwfdagov/cder/foi/label/2006/ 021858s000lblpdf).
80. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005;27(4):361-76.